STOCK TITAN
  1. Home
  2. Sec-filings
  3. CUE
  4. [Form 4] Cue Biopharma, Inc. Insider Trading Activity

Cue Biopharma (CUE) CEO Shao-Lee Lin awarded 327,537-share RSU and PSU package

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Lin Shao-Lee reported acquisition or exercise transactions in this Form 4 filing.

Cue Biopharma, Inc. reported that Chief Executive Officer Shao-Lee Lin received equity awards covering 327,537 shares of Common Stock on July 9, 2026. The awards consist of restricted stock units and performance stock units, and Lin now holds 655,074 Common shares directly following these grants.

Positive

  • None.

Negative

  • None.

Insights

CEO received a sizable stock-based compensation grant, increasing direct equity exposure without open-market buying.

Chief Executive Officer Shao-Lee Lin was granted equity awards tied to 327,537 shares of Common Stock. Part of this grant is in restricted stock units vesting in equal quarterly installments over 48 months, conditioned on continued service with Cue Biopharma, Inc..

The remaining portion is in performance stock units with three stock-price hurdles at $33.00, $38.50, and $44.00 per share. Each tranche vests only if the closing share price meets its target for five consecutive trading days within 24 months from grant; otherwise, the PSUs are forfeited. Following these grants, Lin holds 655,074 shares directly, aligning compensation with future share-price performance.

Insider Lin Shao-Lee
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Common Stock 327,537 $0.00 --
Grant/Award Common Stock 327,537 $0.00 --
Holdings After Transaction: Common Stock — 327,537 shares (Direct)
Footnotes (1)
  1. Represents that grant of restricted stock units ("RSUs"). The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date. Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration.
Equity awards granted 327,537 shares of Common Stock Total share-based awards granted to CEO Shao-Lee Lin on July 9, 2026
Shares held after grant 655,074 shares Direct Common Stock holdings of Shao-Lee Lin following the reported transactions
RSU vesting period 48 months Restricted stock units vest in equal quarterly installments over 48 months from grant
First PSU price target $33.00 per share Closing price required for first PSU tranche to vest for five consecutive trading days
Second PSU price target $38.50 per share Closing price required for second PSU tranche to vest for five consecutive trading days
Third PSU price target $44.00 per share Closing price required for third PSU tranche to vest for five consecutive trading days
PSU performance window 24 months If stock-price targets are not met within 24 months from grant, PSUs are forfeited
restricted stock units financial
"Represents that grant of restricted stock units ("RSUs")."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
performance stock units financial
"Represents the grant of performance stock units ("PSUs")."
Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.
vesting conditions financial
"The PSUs are subject to certain stock-price based vesting conditions"
Vesting conditions are the rules that determine when someone earning company stock or stock options actually gains the right to keep or sell them, typically based on staying with the company for a set time or meeting performance targets. Think of it like keys that unlock gradually — some unlock by calendar date, others only after agreed milestones. Investors care because vesting shapes management incentives, the timing of share sales, and the number of shares that can enter the market, which can affect a company's valuation and ownership mix.
trading days financial
"for a period of five consecutive trading days."
Trading days are the specific days when a stock exchange is open and buying and selling of securities can occur, excluding weekends and exchange-declared holidays. Investors use trading days to measure performance, calculate settlement deadlines and time-sensitive events—think of them as the business hours calendar for markets, where returns, volumes and deadlines are counted only on days the market is operating.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did Cue Biopharma (CUE) disclose about CEO Shao-Lee Lin’s recent stock awards?
Cue Biopharma disclosed that CEO Shao-Lee Lin received equity awards tied to 327,537 shares of Common Stock on July 9, 2026, consisting of restricted stock units and performance stock units as part of compensation.

How many Cue Biopharma (CUE) shares does CEO Shao-Lee Lin hold after the July 2026 grants?
After the July 9, 2026 grants, CEO Shao-Lee Lin directly holds 655,074 shares of Cue Biopharma Common Stock, according to the ownership figure reported following the transactions.

How do Shao-Lee Lin’s restricted stock units vest at Cue Biopharma (CUE)?
The restricted stock units granted to Shao-Lee Lin vest in equal quarterly installments over 48 months from the grant date, contingent on continued service with Cue Biopharma through each vesting date.

What stock price targets apply to Cue Biopharma (CUE) CEO Shao-Lee Lin’s performance stock units?
The performance stock units granted to Shao-Lee Lin vest in three tranches tied to closing share-price targets of $33.00, $38.50, and $44.00, each requiring five consecutive trading days at or above the target.

What happens if Cue Biopharma (CUE) stock does not meet the PSU targets for Shao-Lee Lin?
If Cue Biopharma’s stock fails to reach each PSU price target for five consecutive trading days within 24 months from grant, those performance stock units are automatically forfeited and cancelled without consideration.

Are Shao-Lee Lin’s Cue Biopharma (CUE) stock awards open-market purchases?
No. The Form 4 describes grant or award acquisitions of restricted and performance stock units with a transaction price of $0.00 per share, indicating compensation grants rather than open-market purchases.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lin Shao-Lee
(Last)(First)(Middle)
C/O CUE BIOPHARMA, INC.
40 GUEST STREET
(Street)
BOSTON MASSACHUSETTS 02135
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/09/2026A327,537(1)A$0655,074D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Common Stock(2)07/09/2026A327,537 (2) (2)Common Stock327,537$0327,537D
Explanation of Responses:
1. Represents that grant of restricted stock units ("RSUs"). The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date.
2. Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration.
/s/ Shao-Lee Lin07/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR